Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient's disease, condition, or symptoms.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/01/20 | $28,000,000 | Venture |
Adage Capital Management Averill Master Fund J.W. Childs Associates L.P. | undisclosed |
